Office of Translational Resources

OTR可向CCR pi提供建议和信息，以促进有前途的基础研究转化为临床前模型，并理想地转化为临床。具体而言，OTR将：(1)作为CCR pi的主要联络点和咨询实体，以制定健全的翻译战略。(2)协助pi在CCR， NCI， NIH或校外社区寻找资源，以促进转化和药物开发项目。(3)主办关于药物开发和转化研究重要技术的研讨会和讲习班。(4)加强与具有强烈转化和药物开发兴趣的CCR/NCI/NIH团体的沟通/合作，如分子靶标项目、NCATS、DCTD、NIHF等。(5)改善与NCI/NIH技术转移办公室的接触和互动。(6)协调药物开发协作组织（DDC），为CCR pi在个别项目上提供科学建议。项目负责人可以向DDC提交他们的项目，小组将为个别项目提供具体建议，目标是将基础研究转移到临床研究和/或DDC批准的项目的实验室或合同资源；特别是那些需要大大超出PI和他/她的合作者能力的工作。21财年支持的项目包括：NCGC00413972靶向胰腺和其他实体器官癌症中cd206高水平m2样肿瘤相关巨噬细胞（tam）；雄激素受体拮抗剂治疗前列腺癌的研究肺癌雾化给药；用PROTACs瞄准LZK与霍奇金淋巴瘤、前列腺癌、结直肠癌、卵巢癌和肾细胞癌等多种癌症相关的PK研究；ERGi-USU化合物：早期前列腺癌常见驱动因素的选择性抑制剂。

The OTR is available to offer advice and information to CCR PIs to facilitate translation of promising basic research into preclinical models and ideally into the clinic. Specifically, the OTR will: (1)Serve as a primary point of contact and advisory entity to CCR PIs for the development of sound translational strategies. (2)Assist PIs in finding resources in the CCR, NCI, NIH or in the extramural community that facilitate translational and drug development projects. (3)Sponsor seminars and workshops on technologies important to drug development and translational studies. (4)Strengthen communications/collaborations with CCR/NCI/NIH groups with strong translational and drug development interests such as the Molecular Targets Program, NCATS, DCTD, the NIHF and others. (5)Improve access and interaction with the NCI/NIH Technology Transfer Offices. (6)Coordinate the Drug Development Collaborative (DDC), which provides scientific advice to CCR PIs on individual projects. PIs can present their projects to the DDC and the group will offer recommendations specific for individual projects with the goal of moving basic research into clinical studies and/or laboratory or contract resources for DDC-approved projects; particularly those requiring work significantly beyond the capabilities of the PI and his/her collaborators. Projects supported in FY21 include: NCGC00413972 targeting CD206high M2-like tumor associated macrophages (TAMs) in pancreas and other solid organ cancers; Inverse Agonists of the Androgen Receptor for Treating Prostate Cancer; Aerosolized drug delivery for lung cancer; Targeting LZK with PROTACs; PK studies relevant to a variety of cancers including Hodgkin Lymphoma, Prostate, Colorectal, Ovarian and Renal Cell; ERGi-USU Compounds: Selective Inhibitors of a Common Driver of Early Prostate Cancer.